Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.
Shares of Titan Pharmaceuticals (OTCQB:TTNP) have been stuck in a narrow trading range between $0.45 and $0.65 for the past 4+ months following the surprise decision from the U.S. FDA to issue a complete response letter (CRL) for Probuphine back in late April 2013. We call this decision by the FDA a "surprise", because only five weeks prior to the decision, in March 2013, the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) voted to recommend approval of the product. Titan plans to request a meeting with the FDA to discuss the issues raised in the CRL in the next...
Only subscribers can access this article, which is part of the PRO research library covering 3,590 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: